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In vitro glycorandomization is a rapid chemoenzy-
matic strategy to diversify complex natural product
scaffolds. The glycorandomization sugar activation
pathway is dependent upon the efficient construction
of diverse sugar-1-phosphate libraries. In the context
of the previously evolved GalK Y371H “gatekeeper”
mutation, the active site M173L mutation described
herein presents a kinase with remarkably broadened
substrate range to include 28 diverse natural and un-
natural sugars. Among these new substrates, 6-azido-
6-deoxy-galactose and 6-azido-6-deoxy-glucose pre-
sent unique chemical probes to assess the utility of
an E. coli Y371H/M173L-GalK-overproducing strain to
generate unnatural sugar-1-phosphates in vivo. Re-
markably, the in vivo conversion of both unnatural
sugars rival that demonstrated in vitro. This notable
in vivo success stands as the first step toward
constructing short sugar-activation pathways in vivo
and, ultimately, in vivo natural-product glycorandomi-
zation.
Introduction
Glycosylated natural products remain a key source of
pharmaceutical leads, and, given the essential roles of
their sugar appendages, the development of efficient
methods to rapidly diversify sugars attached to com-
plex natural products is anticipated to enhance drug
discovery efforts [1–5]. Glycorandomization (Figure 1A),
a process centered upon the inherent promiscuity of
secondary metabolite-associated glycosyltransferases,
is one of the latest promising developments toward this
important goal [6, 7]. Critical to the success of glyco-
randomization has been our ability to engineer and/or
evolve two additional promiscuous enzymes—ano-
meric kinases [8–11] and nucleotidylyltransferases [12–
16]. Taken together with the many elegant methods to
synthesize monosaccharide libraries [17–19] and the in-
trinsic substrate flexibility of many secondary metabo-
lite-associated glycosyltransferases, this two-enzyme
short activation pathway allows one to rapidly diversify
the sugars attached to complex natural products [6, 7,
20–22]. The glycorandomization process is further en-
hanced via a final diversification step that relies upon
the use of downstream chemoselective ligation [6, 7].*Correspondence: jsthorson@pharmacy.wisc.eduAs exemplary proof of the concept, recent in vitro gly-
copeptide glycorandomization experiments led to >50
vancomycin derivatives, some of which displayed en-
hanced and distinct biological properties from the par-
ent natural product [6, 7, 23].
Cumulatively, the successful demonstration of in vitro
glycorandomization, the illustration that functional NDP-
sugar pathways can be reassembled in prokaryotes
[24, 25], and the fact that natural and “unnatural”
endogenous sugars are processed in vivo by both
prokaryotes and eukaryotes [26–30] present the foun-
dation from which to approach in vivo glycorandomiza-
tion. For example, the expression of a tandem promis-
cuous sugar-1-kinase (GalK) and nucleotidylyltransferase
(Ep)—essentially an unnatural NDP-sugar factory—in a
natural aglycon-producing host (e.g., the erythromy-
cin-producing Saccharopolyspora) should present the
prospect of generating a glycorandomized library in situ,
the glycorandomized metabolite output of which is
controlled by monosaccharides being fed to the strain
(Figure 1B). Alternatively, expression of the tandem
two gene “NDP-sugar factory” genes in a nonproduc-
ing host (e.g., S. lividans or E. coli), which expresses
a given glycosyltransferase (or glycosyltransferase li-
brary), should also provide a vehicle to accomplish gly-
corandomization via feeding the host with appropriate
aglycon acceptors and unnatural sugar donors (Figure
1C). The key to either in vivo scenario is the ability of
unnatural sugars to enter the host and serve as efficient
substrates of the first enzyme of the short activation
pathway (the flexible anomeric kinase). Toward demon-
strating this first key step, a kinase able to process
sugars bearing unique mass signatures and/or reactive
handles would, in addition to further enhancing library
diversification, greatly simplify the final analysis of
in vivo sugar substrate access and turnover.
To date, we have applied directed enzyme evolution
and relied upon a high throughput galactokinase (GalK)
assay (DNS assay) for the screening of diverse E. coli
GalK variants generated via error-prone PCR to eluci-
date anomeric kinases with broadened substrate spe-
cificity [9]. From this approach, one particular GalK
mutant (Y371H) demonstrated remarkably widened sub-
strate flexibility toward C-2, C-3, C-5, and C-6 sub-
stitutions of D-galactose. Yet, the mutant retained a
stringent requirement for the axial C-4 galactose archi-
tecture. Based upon a homology model with the re-
cently solved L. lactis GalK crystal structure, two highly
conserved active-site residues (D37 and Y223 in E. coli
GalK) are responsible for hydrogen bonding with this
C-4 axial hydroxyl group of the substrate [31]. Satura-
tion mutagenesis at these two critical positions in the
E. coli enzyme failed to provide mutants with enhanced
C-4 sugar flexibility [10], although a parallel study re-
vealed the L. lactis wild-type GalK and Y385H orthologs
(the equivalent to Y371H in the E. coli enzyme) to sur-
prisingly display weak activity toward the C-4 epimer,
glucose [11].
Herein, we report a structure-activity model based
upon the L. lactis active site and its ability to weakly
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658Figure 1. Glycorandomization Overview and
Two Potential Scenarios for an In Vivo Ap-
proach
(A) In vitro glycorandomization utilizes two
enhanced enzymes—E1 (a general kinase)
and E2 (a general nucleotidylyltransferase)—
to generate NDP-sugar substrate libraries to
be utilized by a flexible natural product-
associated glycosyltransferase (GlyT).
(B) In vivo glycorandomization scenario I:
feeding monosaccharides to a natural prod-
uct-producing host engineered to express
the “NDP-sugar factory.” In this scenario,
both the aglycon and glycosyltransferase
are provided by the bacterial host.
(C) In vivo glycorandomization scenario II:
feeding monosaccharides and aglycons to a
nonproducing host engineered to express
the “NDP-sugar factory” and an appropriate
glycosyltransferase or glycosyltransferase li-
brary.utilize glucose to serve as a basis for the design of a s
aspecific engineered E. coli M173L mutant GalK with en-
hanced C-4 and C-6 promiscuity. Moreover, a combina- a
stion of the favorable structure-based (M173L) mutation
with the beneficial mutation previously discovered via c
Gdirected evolution (Y371H) provides an enzyme with
substrate promiscuity that drastically exceeds an addi- C
gtive enhancement for both C-4 and C-6 substitutions.
Most importantly, the additional unnatural sugar sub- (
Gstrates accessed by this new double mutant allow for a
unique opportunity to assess whether unnatural sugars s
bcan enter a bacterial host and serve as efficient sub-
strates of the first enzyme of the glycorandomization L
hpathway (the flexible anomeric kinase). Specifically,
feeding of the unnatural substrate 6-azido-6-deoxy- t
tgalactose (2) or 6-azido-6-deoxy-glucose (26) to an
E. coli host engineered to express M173L-Y371H-GalK l
tfollowed by the rapid fluorescent labeling of substrates
and products via Huisgen 1,3-dipolar cycloaddition re- i
Lvealed the desired unnatural sugar-1-phosphate pro-
duction to occur in vivo under normal fermentation d
2conditions. This result stands as a critical first step in





MStructural Basis for Engineering GalKs
with Expanded Specificity h
uPrior to any available GalK structural information, thedirected evolution of E. coli GalK presented a generalugar anomeric kinase with widened flexibility primarily
t C-5 and C-6 of the sugar substrate [9]. Interestingly,
ll C-4-modified derivatives tested in the previous
tudy failed as substrates for the evolved catalyst. In
ontrast, our latest analysis of the L. lactis wild-type
alK revealed moderate in vitro conversion of various
-4-modified analogs, including 4-azido-4-deoxy-D-
alactose (1), 4-deoxy-D-galactose (5), and D-glucose
7) [11]. The recent structure elucidation of L. lactis
alK [31] potentially allows for a molecular-level as-
essment of this surprising C-4 specificity distinction
etween the E. coli and L. lactis enzymes. With the
. lactis structure as a template, an E. coli-L. lactis GalK
omology model revealed one clear difference between
he sugar binding pockets. Specifically, L182 in wild-
ype L. lactis GalK is near the C-4 carbon atom of ga-
actose (3.85 Å), and, based upon sequence alignment,
his residue is replaced by M173 in E. coli GalK. Model-
ng the C-4 epimer of galactose (D-glucose) within the
. lactis active site predicts the Glc-C-4 equatorial hy-
roxyl to be 3.79 Å from the γ methyl of L182 (Figure
A). However, the identical model in which L182 has
een replaced by methionine (to mimic the E. coli GalK
ctive site) revealed the same Glc-C-4 equatorial
ydroxyl to be 1.72 Å from M173 sulfur (Figure 2B)
nd suggests M173 in E. coli GalK may limit sugar
-4 specificity to galacto-(axial)-configured substrates.
oreover, given the close proximity of the sugar C-6
ydroxyl to M173 in this structural model (2.85 Å) (Fig-
re 2B), we speculate M173 in E. coli GalK may alsolimit C-6 substitutions.
Engineering GalK for In Vivo Glycorandomization
659Figure 2. Modeling D-Glucose Bound to GalK Variants
(A) The active site of L. lactis GalK. (B) The corresponding homology-model of E. coli GalK.Characterization of Engineered E. coli GalK Mutants
A single E. coli GalK M173L mutant was generated and
screened against a panel 45 potential sugar substrates
to test the above hypothesis. As predicted, the E. coli
M173L-engineered mutant displayed moderate D-glu-
cose (7) activity (20% conversion in 3 hr). Moreover,
three additional D-gluco-configured structures, 8, 17,
and 18 (Figures 3 and 4), which were not substrates
of wild-type E. coli GalK (or the evolved E. coli Y371H
mutant), were also substrates of the new structure-
based variant. Although these studies clearly revealed
the structure-based M173L mutant to accept a sub-
strate set distinct to that of the previously evolved
Y371H mutant, in contrast to the structural model de-
scribed above, both mutants failed in the presence of
substrates presenting even moderate C-6 bulk such
as 6-azido-6-deoxy-galactose 2 or 6-azido-6-deoxy-D-
glucose 26. The E. coli double M173L-Y371H mutant
was examined in an attempt to further generalize the
sugar kinase activity. Remarkably, not only did this
double mutant retain the activity of both corresponding
single mutants, but this prodigy demonstrated a sub-
stantial degree of kinase activity toward a variety of
new structures (1–6, 23–28). Most of the new substrates
share modifications at C-4 and/or C-6 with many of
D-gluco origin. It is also noteworthy that three among
this new substrate set are azidosugars (1, 2, and 26),
thereby setting the stage for rapid analysis of in vivo
bioconversion via postbioconversion labeling of sub-
strates and products with a fluorescent tag by using
Huisgen 1,3-cycloaddition [6]. Figures 3 and 4 illustrate
the complete substrate profiles for wild-type E. coli
GalK, the E. coli GalK mutant M173L, Y371H, and
M173L-Y371H.
To better understand the distinct role of the two par-
ticular amino acid residues (M173 and Y371) in deter-
mining the substrate specificity, we chose the native
substrate D-galactose 9, the unique M173L substrate
D-glucose 7, and the unique Y371H substrate L-altrose
21 for complete comparative steady-state kinetic profil-
ing. In comparison to wild-type E. coli GalK, a slight(w2-fold) D-galactose Km increase was observed in all
three variants (M173L, Y371H, and M173L-Y371H) (Ta-
ble 1). Moreover, a comparison of the D-glucose kinetic
parameters for M173L and the L-altrose kinetic values
for Y371H to those of the double mutant with D-glucose
or L-altrose revealed very little change. Although the
determined Vmax values are consistent with observed
3-hr-conversion yields presented in Figure 4, in con-
trast to the notable gain of function (in terms of the
overall number of new M173L-Y371H substrates) il-
lustrated in Figures 3 and 4, this cursory kinetic analy-
sis predicts the gain of function to be additive at best.
In other words, the kinetic analysis suggests the double
mutant should likely accept known M173L and Y371H
substrates but would not forecast an expansion be-
yond this dual substrate set. Yet, although it is difficult
to explain this remarkable gain of function in the
M173L-Y371H variant, the unique ability of this double
mutant to accept compounds 1, 2, and 26 sets the
stage to assess the first step of in vivo glycorandomiza-
tion as described below.
In Vivo Bioconversion of Unnatural Sugars
with an Engineered GalK
In the context of assessing in vivo bioconversion, the
specific M173L-Y371H-1, 2, or 26 relationships are ad-
vantageous for two reasons. First, as described above,
1, 2, and 26 are not substrates for wild-type E. coli
GalK, and, therefore, the use of a standard E. coli host
strain (which contains the inherent wild-type E. coli
GalK) should not interfere with the experimental design.
Second, as previously mentioned, 1, 2, and 26 each of-
fer a unique functional handle to provide for the rapid
installation of a fluorescent label to simplify the chro-
matographic analysis. In this context, 2 and 26 are
equally reactive (>80%) (X.F. and J.S.T., unpublished
data) to the required fluorescent labeling via Husigen
1,3-cycloaddition, whereas 1 is poorly reactive (<10%)
(X.F. and J.S.T., unpublished data). Thus, for the current
in vivo analysis, 1 was excluded. The set selected (2
and 26) still offer the opportunity to test a range of sub-
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660Figure 3. “Natural” and “Unnatural” Substrates of Wild-Type GalK and GalK Mutants
The positions deviating from the natural GalK substrate D-galactose (9) are highlighted in red.strates with distinctly unique in vitro profiles. Specifi- a
6cally, 2 is known to have 44% ± 2% conversion in vitro
in 3 hr, whereas 26 shows 14% ± 3% conversion under t
tthe same conditions.
The unnatural sugars (2 or 26, 4 mM final concentra- i
ttion) were fed to an E. coli host (40 ml culture), which
overexpressed the promiscuous GalK, to assess the l
oY371H-M173L GalK-catalyzed in vivo production of un-
natural sugar-1-phosphates (Figure 5A). After a desig- a
pnated time, the extracts were analyzed via the specific
attachment of a fluorescent tag (30) with 1,3-dipolar p
bcycloaddition [6]. Two controls were processed in par-
allel. The first utilized a strain containing an empty ex- s
Spression vector (pET-15b—the vector used for overex-
pression of the GalK mutants), whereas the second r
“employed a wild-type GalK overexpression strain. The
crude products from each bioconversion were isolated, b
mlabeled via 1,3-dipolar cycloaddition, and analyzed by
fluorescence HPLC and LC-MS. As illustrated in Figure u
h5B, 69% ± 5% conversion of intracellular 6-azido-6-
deoxy-D-galactose (2) was observed, a slight improve- g
cment over the in vitro yield (44% ± 2% conversion). Insimilar manner, 15% ± 4% conversion of intracellular
-azido-6-deoxy-D-glucose (26) was observed, consis-
ent with the in vitro yield (14% ± 3% conversion). Al-
hough the transport of “unnatural” sugars into this typ-
cal cloning E. coli host is less than optimal (e.g.,
ypically ranging from 5%–25%) (J.Y. and J.S.T., unpub-
ished data), the above results are notable for a variety
f reasons. First, the consistency between the in vivo
nd in vitro yields suggests other potential sugars com-
eting for the mutant GalK do not greatly influence the
roduction of the desired product. Should competition
ecome a problem with future “unnatural” sugars, this
ystem is easily amenable to minimal media growth.
econd, the reflected yields also suggest the “unnatu-
al” sugars are not being metabolized via alternative
dead-end” metabolic pathways, some of which could
e genetically excised if problematic to future develop-
ent. Most important, the above result illustrates that
nnatural sugars able to enter the heterologous E. coli
ost are clearly accessible to the engineered, heterolo-
ously-expressed, promiscuous sugar kinase. In the
ontext of strains capable of enhanced uptake of a
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661Figure 4. Percent Conversion of Sugar Substrates by Wild-Type and Mutant GalKs
Standard reaction conditions for all enzymatic reactions: [sugar], 8 mM; [ATP], 14 mM; [MgCl2], 3.5 mM; [enzyme], 15.0 M; reaction time,
180 min. The overall average error is ± 3%.vital component of in vitro glycorandomization—a in our short activation pathway (an engineered sugar-
Table 1. Kinetic Data of the GalK Variants with D-Gal, D-Glc, and L-Alt
D-Gal (9) D-Glc (7) L-Alt (21)
Km Vmax Km Vmax Km Vmax
mM mM , min−1 mM mM , min−1 mM mM , min−1
WT GalK 2.09 (± 0.48) 1.54 (± 0.54) — — — —
M173L 5.87 (± 1.18) 1.95 (± 0.59) 2.57 (± 0.54) 0.02 (± 0.01) — —
Y371H 5.62 (± 0.86) 2.18 (± 0.62) — — 6.04 (± 1.26) 0.16 (± 0.04)
M173L-Y371H 4.59 (± 1.08) 2.26 (± 0.38) 4.02 (± 0.97) 0.02 (± 0.01) 6.28 (± 1.19) 0.07 (± 0.03)broad range of carbohydrates [32–34], this prototype
system is particularly promising.
Significance
The work described herein impacts upon two distinct
areas—enzyme engineering and diversification of
complext natural product libraries with therapeutic
potential. With respect to enzyme engineering, we re-
port the application of structure-based engineering to
provide the most promiscuous anomeric sugar ki-
nase to date—capable of accepting nearly 30 diverse
monosaccharide substrates—that will provide a foun-
dation for the further rational engineering of this vital
class of enzyme. In the context of natural product li-
brary generation, such flexible sugar kinases are arapid chemoenzymatic method to alter the glycosyla-
tion patterns of complex natural products. However,
the general application of in vitro glycorandomization
approach is limited by the two primary issues. First,
expensive substrates/cofactors/enzymes hamper the
overall scale of the process. Second, the in vitro ap-
plication is dependent upon establishing in vitro con-
ditions for an active multienzyme process that can be
severely limited by a variety of factors. A complimen-
tary in vivo process is expected to overcome some,
or all, of these limitations. Our current result illus-
trates the facile entry of unnatural sugars and their
subsequent utilization by an engineered GalK-E. coli
host. We anticipate the current strain to provide the
ability to generate novel sugar-1-phosphate libraries
in vivo, whereas overexpression of the next enzyme
Chemistry & Biology
662Figure 5. In Vivo GalK-Catalyzed Sugar-1-
Phosphate Production
(A) Experimental design overview with
6-azido-6-deoxy-D-galactose (2) as an ex-
ample: step 1, 2 is fed to an E. coli host ex-
pressing the M173L-Y371H GalK double mu-
tant; step 2, after fermentation, the cell pellet
is washed, resuspended, and boiled to delin-
eate in vivo conversion from any potential in
vitro conversion during work up; step 3, the
reactants and products are subsequently la-
beled by using 1,3-dicycloaddition with the
fluorescent tag 30 and analyzed via HPLC
(Phenomenex Luna 5  250 × 4.6 mm C18
reverse phase; 30 mM potassium phosphate
[pH 6.0], 5 mM tetrabutylammonium-hydro-
gensulfate, 2% acetonitrile; 1.0 ml , min−1;
λex = 335 nm, λem = 518 nm).
(B–E) HPLC traces. (B) Labeled-2 standard,
calculated for C26H36N6O8S 592.2, and found
m/z 591.2 [M-H]−. (C) Labeled-2-1-phos-
phate standard, calculated for C26H37N6
O11PS 672.2, and found m/z 671.2 [M-H]−.
(D) 2 with Y371H-M173L GalK-E. coli. (E) 2
with wild-type GalK-E. coli.t1-phosphate nucleotidylyltransferase) will provide cor-
trespondingly diverse NDP-sugar libraries in a similar
dmanner. Although these unique sugar-1-phosphate
t
and NDP-sugar libraries will clearly serve as versatile a
chemical tools for glycobiology, this result more nota-
bly stands as evidence supporting the overall feasi- S
Tbility of in vivo glycorandomization and provides the
wfundamental elements for the eventual in vivo glyco-








The syntheses of 4-azido-4-deoxy-D-galactose (1), 6-ido-6-deoxy- a
D-galactose (2), 6-chloro-6-deoxy-D-galactose (3), 6-bromo-6- b
deoxy-D-galactose (4), 4-deoxy-D-galactose (5), 6-hydroxy- 1
methylene-D-galactose (12), 3-deoxy-D-galactose (14), 6-amino-6- D
deoxy-D-galactose (15), 6-deoxy-6,6-difluoro-D-galactose (20), and p
5-dimethylaminonaphthalene-1-(N-[5-propargylamidepentyl])- c
sulfonamide (30) were reported previously [6, 8, 11]. The syntheses h
of 6-thio-6-deoxy-D-galactose (23), 6-thio-6-deoxy-D-glucose (24), t
and 6-azido-6-deoxy-D-glucose (26) will be reported elsewhere m
(J.L., X.F., and J.S.T., unpublished data), whereas other monosac- p
charide compounds 6–11, 13, 16–19, 21, 22, 25, 27, and 28 were
purchased from Sigma (St. Louis, Missouri), Fisher/Acros Organics C
(Hanover Park, Illinois), or Fluka (Milwaukee, Wisconsin). E. coli T
strains XL1-Blue and BL21 (DE3) were purchased from Stratagene c
(La Jolla, California). Expression vector pET15b was purchased t
from Novagen (Madison, Wisconsin). Enzymes were purchased c
from Promega (Madison, Wisconsin). e
N
cStructure Modeling
The PDB file for the crystal structure of L. lactis wild-type GalK was q
wobtained from the Protein Data Bank, Research Collaboratory for
Structural Bioinformatics, Rutgers University, New Brunswick, New m
wJersey (http://www.rcsb.org/) [31]. The structure modeling was ac-
complished with Swiss-PdbViewer software (version 3.7). L182 was Y
rreplaced by methionine in L. lactis wild-type GalK-galactose struc-ure, and the best rotamors for M182 substitution were selected by
he scoring function of the software. The galactose C-4 axial hy-
roxyl within the resulting minimized mutant structure was inverted
o present the plausible representation of the E. coli wild-type GalK
ctive site bound to D-glucose.
ite-Specific Mutagenesis
he GalK M173L single mutant and M173L-Y371H double mutant
ere generated with the QuikChange II Site-Directed Mutagenesis
it from either wild-type or Y371H template, respectively (Strata-
ene). The corresponding mutated plasmids pGalKM173L and
GalKMLYH were constructed by using PfuUltra DNA polymerase
or mutagenic primer-directed replication from pGalK [8] or pGal-
Y371H [9] template, respectively, with a pair of mutagenic primers
5#-GTAACTGCGGGATCCTGGATCAGCTAATTTCCG-3# and 5#-CGG
AATTAGCTGATCCAGGATCCCGCAGTTAC-3#). Amplification was
ccomplished under the following conditions: 5 l of 10× reaction
uffer, 40 ng template DNA, 120 ng of each oligonucleotide primer,
l dNTPs mixture (2.5 mM), and 2.5 U of PfuUltra high-fidelity
NA polymerase in a total volume of 50 l ddH2O (thermocycler
arameters: initial denaturation, 2 min at 95°C; amplification, 12
ycles, 0.5 min at 95°C, 1 min at 55°C, 6.5 min at 68°C; terminal
old, 5 min at 68°C). The amplified plasmids were treated with DpnI
o digest the parental DNA template and the mutated prodigy plas-
id subsequently used to transform E. coli XL1-blue. The desired
oint mutation was verified by sequencing.
haracterization of GalK Mutants
he GalK Y371H mutant was overexpressed following the pro-
edure previously described for wild-type E. coli GalK [8], whereas
he overexpression of mutants M173L and M173L-Y371H was ac-
omplished at 16°C as described for L. lactis GalK [11]. The mutant
nzymes were purified by using metal affinity chromatography on
i-NTA Spin Columns (QIAGEN, Valencia, California), and fractions
ontaining homogenous protein were collected, concentrated, and
uantified by using the Bradford protein assay [35]. The DNS assay
as used to assess the substrate specificity of the purified GalK
utants as previously described [8]. A library of 45 different sugars
as screened with each mutant (M173L, Y371H, and M173L-
371H). For each sugar, the DNS assay was used to monitor the
eaction progress, and control assays in the absence of enzyme or
Engineering GalK for In Vivo Glycorandomization
663sugar were performed in parallel. Standard curves for each sugar
were prepared as described [8]. Each reaction contained 15.0 M
enzyme, 8 mM sugar, 14 mM ATP, and 3.5 mM MgCl2 to assess
general percent conversion. For total conversion assays, upon final
addition of the enzyme, the reactions were incubated at 37°C for 3
hr after which the reactions were quenched with MeOH, centri-
fuged (10 min, 12,000 rpm), and then the supernatant (diluted 20-
fold) submitted for LC-MS and MS/MS analysis. All assays were
minimally run in triplicate with the average yields reported.
For monosaccharide kinetic determinations, the sugar concen-
tration was varied over a range of 1–8 mM, under saturating ATP
(14 mM), minimally in triplicate. Reaction progress was assessed
via the DNS assay wherein a change in absorbance at 575 nm as
a function of time was obtained and the initial velocity determined
by the slope of the linear phase in the progress curve. The kinetic
data was analyzed with Enzyme Kinetics Module software (SSPS,
Inc., Chicago, Illinois) as previously described [8].
In Vivo Conversion Analysis
The GalK double mutant pGalKMLYH-E. coli was overexpressed at
16°C via induction of a 40 ml of culture at an OD600 w0.7 with IPTG
(1 mM). The induced cultures were incubated with shaking (140
rpm) for 1 hr, and 100 mM of 2 or 26 was added to the culture to a
final concentration of 4 mM. The cultures were further incubated at
16°C with shaking (140 rpm) for 16 hr. The cells were harvested by
centrifugation (15 min, 12,000 rpm), and the recovered cell pellet
(380 mg) was washed until DNS analysis of the wash solution re-
vealed no remaining endogenous extracellular-free monosaccha-
ride (2 × 20 ml sodium phosphate buffer) to assess bioconversion.
The pellet was frozen, thawed, resuspended in H2O:MeOH (1:1),
heated at 100°C for 15 min, and then sonicated 5 × 45 s on ice. An
assay of this crude extract for GalK activity revealed all enzyme
had been inactivated, and, thus, any final conversion detected is
clearly due to in vivo conversion. Cell debris was collected by cen-
trifugation (15 min, 12,000 rpm) and lyophilized to give the pale
white solid (18 mg).
The amount of the fluorescent tag (30) needed for 1,3-dipolar
cycloaddition was roughly calculated based upon the maximum
amount of intracellular azidosugar conversion. A rough determina-
tion of extracellular-free sugar concentration was provided by pel-
leting the cells and assaying the supernatant via our DNS assay
to assess the amount of intracellular sugar conversion. This was
accomplished both at the beginning of the bioconversion experi-
ment and at the end of the 16 hr incubation, the difference (above
background based upon an assay of the same host in the same
growth media but in the absence of endogenous unnatural sugar)
we attributed to the maximum attainable intracellular free sugar.
To a solution containing all the soluble crude product in 160 l of
H2O:MeOH (1:1) was added 10 mol 30 and 3.2 mol of CuI, fol-
lowed by heating to 50°C for 24 hr [6]. The reaction mixture was
subsequently centrifuged to remove CuI, and the supernatant (di-
luted 2-fold) directly analyzed by HPLC and LC-MS. The yield cal-
culation was based on the integration of the peak area for the sub-
strates and products and corresponds to only intracellular
reactants and products. All assays were minimally run in triplicate
with the average yield reported.
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